ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / SRZN
VALN (46) ETRA (43) ENTX (41) RGNX (27) ⌘ Pro Terminal →

Surrozen Inc. (SRZN) — RQD Stock Rating Cockpit

$29.02 -0.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.96

Surrozen Inc. (SRZN) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $516.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SRZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Surrozen Inc. (NASDAQ: SRZN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $29.02 (-0.07% 1D, market cap $516.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SRZN ranks #533 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SRZN compare to VALN and ETRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRZN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VALN (Valneva SE) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $517.1M) and ETRA (Electra Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $508.4M). Among the 5-stock peer group, SRZN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRZN?
▼

Per SRZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824893), Surrozen Inc. generated $3.5M in revenue (-67.4% YoY), -$242.0M in net income, and -$30.4M in free cash flow against $98.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $28.96 (-0.20%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk E
Cash (8)Whales (13)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
$40 Bull$26 Base$21 Bear
📬 FREE SRZN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRZN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY SRZN SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$23.51+6.9% Next Q
Q2 (-2Q)
32
Grade E$25.14+17.5% Next Q
Q3 (-1Q)
34
Grade E$29.53-1.7% Next Q
Current
37
Grade D-$29.02-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRZN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRZN currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.52) and Max Pain ($30.47) forces dealer call-delta covering toward $39.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SRZN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
57.630 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE67% OF RANGE
L: $11$29.02H: $38
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on SRZN

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -5.79% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (40)

16/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like SRZN
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRZN)

  • ✓Walkthrough of SRZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
SRZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -9.51%📐 HORIZONTAL RANGE
2026-11-03O $29.46H $29.46L $29.02C $29.02VOL 231.9K
RES: $42.86SUP: $14.67SMA50: $24.52SMA200: $25.19
$39.35$33.06$26.77$20.48$14.19RES $42.86SUP $14.67$29.022026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRZN Butterfly Map → + Track SRZN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -67.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SRZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SRZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRZN)

Health Care Rank #533 of 1015 ⚔️ VALN vs SRZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRZN vs. VALN, ETRA, ENTX, RGNX)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Surrozen Inc. (SRZN) ranks #533 by composite RQD confidence (37/100, grade D-) and #433 by equity capitalization ($516.9M). Within this direct 5-issuer industry benchmark cohort, SRZN leads on earnings valuation at N/A trailing P/E, while ENTX leads on capital efficiency and profitability with -33.6% ROIC and 0.0% gross margin. VALN currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with SRZN at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SRZN ACTIVE
Surrozen Inc.
D- 37/100 — — -35.0% -0.07% $516.9M Benchmark Subject
VALN
Valneva SE
D 46/100 — — — -2.38% $517.1M /valn-vs-srzn →
ETRA
Electra Therapeutics Inc.
D- 43/100 — — — -9.75% $508.4M /etra-vs-srzn →
ENTX
Entera Bio Ltd.
D- 41/100 — 0.0% -33.6% -3.44% $556.6M /entx-vs-srzn →
RGNX
REGENXBIO Inc.
E 27/100 — — -35.0% -0.56% $475.3M /rgnx-vs-srzn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001824893 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Surrozen Inc. (SRZN) reported GAAP revenue of $3.5M (-67.4% vs. FY2024 revenue of $10.7M , and -97.3% cumulative change since FY2023) , GAAP net income of -$242.0M, operating cash flow of -$30.2M, and free cash flow of -$30.4M (-72.0% YoY). On the balance sheet, SRZN closed FY2025 with $98.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $3.5M -$242.0M -$30.2M -$30.4M $98.7M —
FY2024 (FY) 2024-12-31 $10.7M -$63.6M -$17.6M -$17.7M $48.5M —
FY2023 (FY) 2023-12-31 $128.2M -$43.0M -$40.4M -$40.4M — —

3. SRZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Surrozen Inc. (NASDAQ: SRZN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $29.02 (-0.07% 1D, market cap $516.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SRZN ranks #533 in composite RQD confidence.

How does SRZN compare to VALN and ETRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SRZN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VALN (Valneva SE) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $517.1M) and ETRA (Electra Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC —, cap $508.4M). Among the 5-stock peer group, SRZN leads on earnings multiple (N/A) while ENTX leads on capital efficiency (-33.6% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRZN?

Per SRZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001824893), Surrozen Inc. generated $3.5M in revenue (-67.4% YoY), -$242.0M in net income, and -$30.4M in free cash flow against $98.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRZN trading relative to its 50-day, 200-day, and 52-week technical levels?

SRZN last traded at $29.02 (-0.07% on volume of 159,262 shares), positioning the stock +18.35% above its 50-day simple moving average ($24.52) and +15.20% above its 200-day simple moving average ($25.19). Across its 52-week range of $11.39 to $37.83, SRZN sits at the 66.7% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($25.39 to $32.65).

Direct Sub-Reports: SRZN RQD Cockpit SRZN 12M Forecast SRZN Earnings & Move SRZN Dividends & DRIP SRZN Insiders & 13F SRZN Whale Options SRZN Profit Sankey SRZN News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

SRZN — Surrozen Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Surrozen Inc. (SRZN) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $29.02 (-0.07% 1D, market capitalization $516.9M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -5.79%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Surrozen Inc. Is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. Per the market data, its gross margin is 0%. FY 2025 revenue was $3.5M, indicating minimal current commercial revenue.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Surrozen Inc. (SRZN) reported $3.5M in annual revenue (up from $10.7M in FY2024, -67.4% YoY) and -$242.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($128.2M revenue, -$43.0M net income) through FY2025, SRZN scaled operating cash flow to -$30.2M and free cash flow to -$30.4M, backed by $98.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -5.79% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $11.39 – $37.83 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph reports no upstream or downstream links, no sector correlations, and no proprietary signals.

  • Key Question #1: Can SRZN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $3.5M and free cash flow of -$30.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is SRZN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SRZN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Surrozen Inc. (SRZN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SRZN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRZN Bull vs. Bear Conversation Board — What's Your Call at $29.02?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRZN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on SRZN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $37.46 (+29.0%)
📌 Pinned Debate

Institutional whale-flow pillar scores 14 of 20, the strongest pillar in the RQD rating, and cash reported at $89.2M in FY 2025.

The street is overcomplicating Surrozen Inc. (SRZN). Institutional whale-flow pillar scores 14 of 20, the strongest pillar in the RQD rating, and cash reported at $89.2M in FY 2025.. With an RQD score of 37/100 (D-) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $31.36.

ArenaChamp_24 🐂 BULL

@MidwestValue Agree on the RQD 37/100 quality, though with 1.0 beta I'm scaling in with half-size at $29.04 and keeping dry powder in case we test $27.01.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $24.10 (-17.0%)
Spot @ $29.04

ROIC of -35%, FCF yield of -5.79%, Piotroski F of 2/9, and FY 2025 net loss of -$242.0M on $3.5M revenue.

I respect the product at Surrozen Inc., but the stock at $29.04 is a different story. ROIC of -35%, FCF yield of -5.79%, Piotroski F of 2/9, and FY 2025 net loss of -$242.0M on $3.5M revenue.. FCF yield is -5.79% and RQD sits at 37/100 (D-) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE